This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The FDA recently finalized regulatory guidance for compounded animal medications from bulk drug substances for use in non-food-producing animals, impacting the way compounded drugs can be used, documented, ordered, and prescribed. Bulk drug substances are the raw active ingredients most compounded medications are made from.
Implementation of GFI #256 Earlier this year, the FDA finalized regulatory guidance for compounded medications, known as GFI #256. If GFI is affecting your practice’s ability to get compounded medications for office use, partnering with a trusted 503B outsourcing facility can help you eliminate risks of limited ordering.
Nitrosamines’ emergence in drug products Nitrosamines are organic chemical compounds that may be present in low levels in a wide variety of products such as processed meats, cosmetics and cigarette smoke. FDA and other global regulatory agencies have issued public health alerts and guidance documents for manufacturers.
When combined with the challenges of living with a disability, these individuals may encounter compounded discrimination and systemic biases. https ://www.federalregister.gov/documents/2024/03/29/2024-06469/revisions-to-ombs-statistical-policy- directive-no-15-standards-for-maintaining-collecting-and 2 National Minority Quality Forum.
From alcohols to quaternary ammonium compounds, each type of agent has a unique mode of action, with varying degrees of efficacy. In addition, several pieces of documentation will be required to support the API qualification, e.g. pharmacopeial compliance. There are many other aspects to take into consideration.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content